<?xml version='1.0' encoding='utf8' standalone='yes'?>
<collection><document><id>28418444</id><infon key="title">Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.</infon><infon key="pmid">28418444</infon><infon key="pmcid">PMC5599323</infon><infon key="doi">10.1001/jamaoncol.2017.0424</infon><infon key="year">2017</infon><infon key="month">4</infon><infon key="day">19</infon><infon key="journal">JAMA oncology</infon><infon key="journalISO">JAMA Oncol</infon><infon key="authors">Fergus J Couch, Hermela Shimelis, Chunling Hu, Steven N Hart, Eric C Polley, Jie Na, Emily Hallberg, Raymond Moore, Abigail Thomas, Jenna Lilyquist, Bingjian Feng, Rachel McFarland, Tina Pesaran, Robert Huether, Holly LaDuca, Elizabeth C Chao, David E Goldgar, Jill S Dolinsky</infon><infon key="chemicals">C000614131|CDKN2A protein, human	D018797|Cell Cycle Proteins	D019941|Cyclin-Dependent Kinase Inhibitor p16	D050763|Cyclin-Dependent Kinase Inhibitor p18	D004268|DNA-Binding Proteins	D000076164|Fanconi Anemia Complementation Group N Protein	D051856|Fanconi Anemia Complementation Group Proteins	C094443|G-T mismatch-binding protein	C501486|MLH1 protein, human	C121766|MRE11 protein, human	C112156|NBN protein, human	D025542|Neurofibromin 1	D009687|Nuclear Proteins	C512790|PALB2 protein, human	C448305|RAD51C protein, human	C112629|RAD51D protein, human	D025521|Tumor Suppressor Proteins	C102449|BARD1 protein, human	D044767|Ubiquitin-Protein Ligases	D064447|Checkpoint Kinase 2	C576324|ATM protein, human	D064007|Ataxia Telangiectasia Mutated Proteins	C578634|CHEK2 protein, human	D000076228|MRE11 Homologue Protein	D017766|Acid Anhydride Hydrolases	C112158|Rad50 protein, human	C094934|PMS2 protein, human	C497172|MSH2 protein, human	D000070976|Mismatch Repair Endonuclease PMS2	D000070957|MutL Protein Homolog 1	D051718|MutS Homolog 2 Protein	C000618935|BRIP1 protein, human	D020365|RNA Helicases	D045643|DNA Repair Enzymes</infon><infon key="meshHeadings">Descriptor|D017766|N|Acid Anhydride Hydrolases	Descriptor|D000328|N|Adult	Descriptor|D064007|N|Ataxia Telangiectasia Mutated Proteins~Qualifier|Q000235|Y|genetics	Descriptor|D001943|N|Breast Neoplasms~Qualifier|Q000235|Y|genetics	Descriptor|D016022|N|Case-Control Studies	Descriptor|D018797|N|Cell Cycle Proteins~Qualifier|Q000235|N|genetics	Descriptor|D064447|N|Checkpoint Kinase 2~Qualifier|Q000235|Y|genetics	Descriptor|D019941|N|Cyclin-Dependent Kinase Inhibitor p16	Descriptor|D050763|N|Cyclin-Dependent Kinase Inhibitor p18~Qualifier|Q000235|N|genetics	Descriptor|D045643|N|DNA Repair Enzymes~Qualifier|Q000235|N|genetics	Descriptor|D004268|N|DNA-Binding Proteins~Qualifier|Q000235|Y|genetics	Descriptor|D044465|N|European Continental Ancestry Group~Qualifier|Q000235|N|genetics	Descriptor|D000076164|N|Fanconi Anemia Complementation Group N Protein	Descriptor|D051856|N|Fanconi Anemia Complementation Group Proteins	Descriptor|D005260|N|Female	Descriptor|D020022|Y|Genetic Predisposition to Disease	Descriptor|D005820|N|Genetic Testing	Descriptor|D018095|N|Germ-Line Mutation	Descriptor|D006801|N|Humans	Descriptor|D000076228|N|MRE11 Homologue Protein	Descriptor|D008875|N|Middle Aged	Descriptor|D000070976|N|Mismatch Repair Endonuclease PMS2~Qualifier|Q000235|N|genetics	Descriptor|D000070957|N|MutL Protein Homolog 1~Qualifier|Q000235|N|genetics	Descriptor|D051718|N|MutS Homolog 2 Protein~Qualifier|Q000235|N|genetics	Descriptor|D025542|N|Neurofibromin 1~Qualifier|Q000235|N|genetics	Descriptor|D009687|N|Nuclear Proteins~Qualifier|Q000235|Y|genetics	Descriptor|D010051|N|Ovarian Neoplasms~Qualifier|Q000235|Y|genetics	Descriptor|D010641|N|Phenotype	Descriptor|D020365|N|RNA Helicases~Qualifier|Q000235|N|genetics	Descriptor|D012307|N|Risk Factors	Descriptor|D025521|N|Tumor Suppressor Proteins~Qualifier|Q000235|Y|genetics	Descriptor|D044767|N|Ubiquitin-Protein Ligases~Qualifier|Q000235|Y|genetics</infon><infon key="supplementaryMesh"></infon><infon key="publicationTypes">Journal Article</infon><passage><infon key="section">title</infon><offset>0</offset><text>Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.</text></passage><passage><infon key="section">abstract</infon><offset>81</offset><text>Germline pathogenic variants in BRCA1 and BRCA2 predispose to an increased lifetime risk of breast cancer. However, the relevance of germline variants in other genes from multigene hereditary cancer testing panels is not well defined.</text></passage><passage><infon key="section">abstract</infon><offset>315</offset><text>To determine the risks of breast cancer associated with germline variants in cancer predisposition genes.</text></passage><passage><infon key="section">abstract</infon><offset>420</offset><text>A study population of 65 057 patients with breast cancer receiving germline genetic testing of cancer predisposition genes with hereditary cancer multigene panels. Associations between pathogenic variants in non-BRCA1 and non-BRCA2 predisposition genes and breast cancer risk were estimated in a case-control analysis of patients with breast cancer and Exome Aggregation Consortium reference controls. The women underwent testing between March 15, 2012, and June 30, 2016.</text></passage><passage><infon key="section">abstract</infon><offset>892</offset><text>Breast cancer risk conferred by pathogenic variants in non-BRCA1 and non-BRCA2 predisposition genes.</text></passage><passage><infon key="section">abstract</infon><offset>992</offset><text>The mean (SD) age at diagnosis for the 65 057 women included in the analysis was 48.5 (11.1) years. The frequency of pathogenic variants in 21 panel genes identified in 41 611 consecutively tested white women with breast cancer was estimated at 10.2%. After exclusion of BRCA1, BRCA2, and syndromic breast cancer genes (CDH1, PTEN, and TP53), observed pathogenic variants in 5 of 16 genes were associated with high or moderately increased risks of breast cancer: ATM (OR, 2.78; 95% CI, 2.22-3.62), BARD1 (OR, 2.16; 95% CI, 1.31-3.63), CHEK2 (OR, 1.48; 95% CI, 1.31-1.67), PALB2 (OR, 7.46; 95% CI, 5.12-11.19), and RAD51D (OR, 3.07; 95% CI, 1.21-7.88). Conversely, variants in the BRIP1 and RAD51C ovarian cancer risk genes; the MRE11A, RAD50, and NBN MRN complex genes; the MLH1 and PMS2 mismatch repair genes; and NF1 were not associated with increased risks of breast cancer.</text></passage><passage><infon key="section">abstract</infon><offset>1869</offset><text>This study establishes several panel genes as high- and moderate-risk breast cancer genes and provides estimates of breast cancer risk associated with pathogenic variants in these genes among individuals qualifying for clinical genetic testing.</text></passage></document>
</collection>